Titre : Microcirculation

Microcirculation : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement Inactivating Agents
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Microcirculation : Questions médicales les plus fréquentes", "headline": "Microcirculation : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Microcirculation : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-22", "dateModified": "2025-02-16", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Microcirculation" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Circulation sanguine", "url": "https://questionsmedicales.fr/mesh/D001775", "about": { "@type": "MedicalCondition", "name": "Circulation sanguine", "code": { "@type": "MedicalCode", "code": "D001775", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G09.330.100" } } }, "about": { "@type": "MedicalCondition", "name": "Microcirculation", "alternateName": "Microcirculation", "code": { "@type": "MedicalCode", "code": "D008833", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Can Ince", "url": "https://questionsmedicales.fr/author/Can%20Ince", "affiliation": { "@type": "Organization", "name": "Department of Intensive Care, Erasmus MC, University Medical Center, Rotterdam, 's-Gravendijkwal 230, 3015 CE Rotterdam, the Netherlands." } }, { "@type": "Person", "name": "Daniel De Backer", "url": "https://questionsmedicales.fr/author/Daniel%20De%20Backer", "affiliation": { "@type": "Organization", "name": "Department of Intensive Care, CHIREC Hospitals, Université Libre de Bruxelles, Belgium." } }, { "@type": "Person", "name": "Matthias P Hilty", "url": "https://questionsmedicales.fr/author/Matthias%20P%20Hilty", "affiliation": { "@type": "Organization", "name": "Department of Intensive Care, Erasmus MC, University Medical Center, Rotterdam, The Netherlands." } }, { "@type": "Person", "name": "Sonal Pruthi", "url": "https://questionsmedicales.fr/author/Sonal%20Pruthi", "affiliation": { "@type": "Organization", "name": "Division of Cardiology, Department of Medicine, NYU Langone Health, 550 First Avenue, New York, NY 10016, USA." } }, { "@type": "Person", "name": "Emaad Siddiqui", "url": "https://questionsmedicales.fr/author/Emaad%20Siddiqui", "affiliation": { "@type": "Organization", "name": "Division of Cardiology, Department of Medicine, NYU Langone Health, 550 First Avenue, New York, NY 10016, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s.", "datePublished": "2023-05-04", "url": "https://questionsmedicales.fr/article/37149117", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clim.2023.109629" } }, { "@type": "ScholarlyArticle", "name": "Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition.", "datePublished": "2023-01-14", "url": "https://questionsmedicales.fr/article/36732204", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.blre.2023.101041" } }, { "@type": "ScholarlyArticle", "name": "Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.", "datePublished": "2023-04-18", "url": "https://questionsmedicales.fr/article/37072660", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12325-023-02510-4" } }, { "@type": "ScholarlyArticle", "name": "Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial.", "datePublished": "2022-08-09", "url": "https://questionsmedicales.fr/article/35945604", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12931-022-02126-2" } }, { "@type": "ScholarlyArticle", "name": "Antibiofilm agents with therapeutic potential against enteroaggregative Escherichia coli.", "datePublished": "2022-10-06", "url": "https://questionsmedicales.fr/article/36201560", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pntd.0010809" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes physiologiques respiratoires et circulatoires", "item": "https://questionsmedicales.fr/mesh/D002943" }, { "@type": "ListItem", "position": 3, "name": "Phénomènes physiologiques cardiovasculaires", "item": "https://questionsmedicales.fr/mesh/D002320" }, { "@type": "ListItem", "position": 4, "name": "Circulation sanguine", "item": "https://questionsmedicales.fr/mesh/D001775" }, { "@type": "ListItem", "position": 5, "name": "Microcirculation", "item": "https://questionsmedicales.fr/mesh/D008833" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Microcirculation - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Microcirculation", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Microcirculation", "description": "Comment évaluer la microcirculation ?\nQuels tests sont utilisés pour diagnostiquer des troubles ?\nQuels signes indiquent une altération de la microcirculation ?\nLa biopsie peut-elle aider au diagnostic ?\nQuels examens d'imagerie sont recommandés ?", "url": "https://questionsmedicales.fr/mesh/D008833?mesh_terms=Complement+Inactivating+Agents&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Microcirculation", "description": "Quels symptômes sont liés à une mauvaise microcirculation ?\nComment la microcirculation affecte-t-elle la peau ?\nLes troubles de la microcirculation causent-ils des douleurs ?\nQuels signes d'alerte nécessitent une consultation ?\nLa fatigue peut-elle être liée à la microcirculation ?", "url": "https://questionsmedicales.fr/mesh/D008833?mesh_terms=Complement+Inactivating+Agents&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Microcirculation", "description": "Comment prévenir les troubles de la microcirculation ?\nLe contrôle du poids est-il important ?\nL'hydratation joue-t-elle un rôle ?\nLe stress affecte-t-il la microcirculation ?\nLes pauses au travail sont-elles bénéfiques ?", "url": "https://questionsmedicales.fr/mesh/D008833?mesh_terms=Complement+Inactivating+Agents&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Microcirculation", "description": "Quels traitements améliorent la microcirculation ?\nLes exercices physiques aident-ils la microcirculation ?\nY a-t-il des traitements naturels pour la microcirculation ?\nLa thérapie par compression est-elle efficace ?\nLes changements alimentaires influencent-ils la microcirculation ?", "url": "https://questionsmedicales.fr/mesh/D008833?mesh_terms=Complement+Inactivating+Agents&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Microcirculation", "description": "Quelles complications peuvent survenir ?\nLa microcirculation affecte-t-elle la cicatrisation ?\nLes maladies cardiovasculaires sont-elles liées ?\nPeut-on développer des neuropathies ?\nLes troubles rénaux sont-ils possibles ?", "url": "https://questionsmedicales.fr/mesh/D008833?mesh_terms=Complement+Inactivating+Agents&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Microcirculation", "description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il la microcirculation ?\nLe diabète affecte-t-il la microcirculation ?\nLe mode de vie sédentaire est-il un risque ?\nLe tabagisme a-t-il un impact ?", "url": "https://questionsmedicales.fr/mesh/D008833?mesh_terms=Complement+Inactivating+Agents&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer la microcirculation ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques comme la capillaroscopie et l'imagerie par fluorescence sont utilisées." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour diagnostiquer des troubles ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests de perfusion tissulaire et les analyses de sang peuvent être effectués." } }, { "@type": "Question", "name": "Quels signes indiquent une altération de la microcirculation ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des douleurs, des engourdissements ou des changements de couleur de la peau." } }, { "@type": "Question", "name": "La biopsie peut-elle aider au diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une biopsie peut révéler des anomalies dans les petits vaisseaux sanguins." } }, { "@type": "Question", "name": "Quels examens d'imagerie sont recommandés ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'échographie Doppler et l'IRM peuvent évaluer la circulation sanguine microcirculatoire." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une mauvaise microcirculation ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des douleurs, des engourdissements et des ulcères cutanés." } }, { "@type": "Question", "name": "Comment la microcirculation affecte-t-elle la peau ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Une mauvaise microcirculation peut entraîner des changements de couleur et des lésions cutanées." } }, { "@type": "Question", "name": "Les troubles de la microcirculation causent-ils des douleurs ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs peuvent survenir en raison d'une perfusion insuffisante des tissus." } }, { "@type": "Question", "name": "Quels signes d'alerte nécessitent une consultation ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs persistantes, des engourdissements ou des changements cutanés doivent être évalués." } }, { "@type": "Question", "name": "La fatigue peut-elle être liée à la microcirculation ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une mauvaise circulation peut entraîner une fatigue générale et un manque d'énergie." } }, { "@type": "Question", "name": "Comment prévenir les troubles de la microcirculation ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir un mode de vie actif, une alimentation équilibrée et éviter le tabac aide." } }, { "@type": "Question", "name": "Le contrôle du poids est-il important ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un poids santé réduit le risque de troubles circulatoires et améliore la microcirculation." } }, { "@type": "Question", "name": "L'hydratation joue-t-elle un rôle ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une bonne hydratation est essentielle pour maintenir une circulation sanguine optimale." } }, { "@type": "Question", "name": "Le stress affecte-t-il la microcirculation ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut nuire à la circulation sanguine et à la microcirculation." } }, { "@type": "Question", "name": "Les pauses au travail sont-elles bénéfiques ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, faire des pauses régulières aide à améliorer la circulation, surtout en position assise." } }, { "@type": "Question", "name": "Quels traitements améliorent la microcirculation ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments vasodilatateurs et des thérapies physiques peuvent être prescrits." } }, { "@type": "Question", "name": "Les exercices physiques aident-ils la microcirculation ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier favorise la circulation sanguine et améliore la microcirculation." } }, { "@type": "Question", "name": "Y a-t-il des traitements naturels pour la microcirculation ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des compléments comme le ginkgo biloba peuvent soutenir la microcirculation." } }, { "@type": "Question", "name": "La thérapie par compression est-elle efficace ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les bas de compression peuvent aider à améliorer la circulation dans les membres." } }, { "@type": "Question", "name": "Les changements alimentaires influencent-ils la microcirculation ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en antioxydants et en oméga-3 peut améliorer la microcirculation." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des ulcères, des infections et des gangrènes dans les extrémités." } }, { "@type": "Question", "name": "La microcirculation affecte-t-elle la cicatrisation ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une mauvaise microcirculation peut retarder la cicatrisation des plaies." } }, { "@type": "Question", "name": "Les maladies cardiovasculaires sont-elles liées ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des troubles de la microcirculation peuvent augmenter le risque de maladies cardiovasculaires." } }, { "@type": "Question", "name": "Peut-on développer des neuropathies ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une mauvaise circulation peut entraîner des neuropathies périphériques." } }, { "@type": "Question", "name": "Les troubles rénaux sont-ils possibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une altération de la microcirculation peut affecter la fonction rénale." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'obésité, le diabète, le tabagisme et l'hypertension sont des facteurs de risque majeurs." } }, { "@type": "Question", "name": "L'âge influence-t-il la microcirculation ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vieillissement peut altérer la microcirculation et augmenter les risques associés." } }, { "@type": "Question", "name": "Le diabète affecte-t-il la microcirculation ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diabète peut endommager les petits vaisseaux sanguins, affectant la microcirculation." } }, { "@type": "Question", "name": "Le mode de vie sédentaire est-il un risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire augmente le risque de troubles de la microcirculation." } }, { "@type": "Question", "name": "Le tabagisme a-t-il un impact ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme nuit à la circulation sanguine et aggrave les problèmes de microcirculation." } } ] } ] }

Sources (10000 au total)

Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition.

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening, acquired disease in which blood cells lacking complement regulatory proteins are destroyed because of uncontrolled complement act...

Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.

Hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) is complement-mediated due to the lack of complement inhibitors in the hemopoietic cell membranes, making complement inhibition the best approach... The expert recommendations presented here were created using a Delphi-like process by a group of expert PNH specialists across Central Europe. Based on an initial advisory board meeting discussion, re... Using a systematic approach, literature databases were searched for relevant studies, and 50 articles were reviewed by the experts and included as supporting evidence.... Implementation of these recommendations uniformly across healthcare institutions will promote the best use of complement inhibition in managing PNH, and has the potential to positively impact patient ...

Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial.

The efficacy and safety of complement inhibition in COVID-19 patients is unclear.... A multicenter randomized controlled, open-label trial. Hospitalized COVID-19 patients with signs of systemic inflammation and hypoxemia (PaO... 81 patients were randomly assigned to zilucoplan (n = 55) or the control group (n = 26). 78 patients were included in the safety and primary analysis. Most were men (87%) and the median age was 63 yea... Administration of zilucoplan to COVID-19 patients in this proof-of-concept randomized trial was well tolerated under antibiotic prophylaxis. While not reaching statistical significance, indicators of ...

Antibiofilm agents with therapeutic potential against enteroaggregative Escherichia coli.

Enteroaggregative Escherichia coli (EAEC) is a predominant but neglected enteric pathogen implicated in infantile diarrhoea and nutrient malabsorption. There are no non-antibiotic approaches to dealin... We used EAEC strains, 042 and MND005E in a medium-throughput crystal violet-based antibiofilm screen. Hits were confirmed in concentration-dependence, growth kinetic and time course assays and activit... In all, five compounds (1.25%) reproducibly inhibited biofilm accumulation by at least one strain by 30-85% while inhibiting growth by under 10%. Hits exhibited potent antibiofilm activity at concentr... This study identified five compounds, not previously described as anti-adhesins or Gram-negative antibacterials, with significant EAEC antibiofilm activity. Molecule, MMV687800 targets the EAEC Aap. I...

Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.

In the absence of head-to-head trials, this study compared treatment outcomes with the C3 complement inhibitor pegcetacoplan versus the C5 complement inhibitor eculizumab or ravulizumab in complement ... A matching-adjusted indirect comparison was conducted using individual patient data from the pegcetacoplan arm of the PRINCE trial (NCT04085601; n = 34) and aggregate data from the ravulizumab (n = 12... After weighting, treatment with pegcetacoplan was associated with statistically significant improvements in most clinical endpoints compared with ravulizumab or eculizumab treatment. These included: g... Pegcetacoplan provides clinical benefits as first-line treatment for complement inhibitor-naïve patients with PNH.... ClinicalTrials.gov identifier, NCT04085601....

Prevalence of geographic atrophy in Nordic countries and number of patients potentially eligible for intravitreal complement inhibitor treatment: A systematic review with meta-analyses and forecasting study.

We systematically reviewed the literature on the prevalence of geographic atrophy (GA) in Nordic populations, conducted meta-analyses on age-stratified estimates, and calculated current and future num...

Severe refractory warm autoimmune haemolytic anaemia after the SARS-CoV-2 Pfizer-BioNTech vaccine (BNT162b2 mRNA) managed with emergency splenectomy and complement inhibition with eculizumab.

A male in his teens with a history of liver transplant for biliary atresia (aged 2 years) and autoimmune haemolytic anaemia (AIHA, aged 6 years) presented with jaundice, dark urine, fatigue and chest ...

Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors.

Although complement component 5 inhibitors (C5is) eculizumab and ravulizumab improve paroxysmal nocturnal hemoglobinuria (PNH) outcomes, patients may experience persistent anemia. This post hoc analys... Patients with PNH and hemoglobin ≥10.0 g/dL at baseline of PADDOCK (N = 6), PRINCE (N = 8), and PEGASUS (N = 11) were included. Before receiving pegcetacoplan, PADDOCK and PRINCE patients were C5i-nai... From baseline to week 16, mean (SD) hemoglobin concentrations increased in C5i-naive patients (PADDOCK: 10.5 [0.4] to 12.7 [1.1] g/dL; PRINCE: 11.3 [1.0] to 14.0 [1.3] g/dL) and those with suboptimal ... Patients with PNH and mild/moderate anemia who were C5i-naive or who had suboptimal hemoglobin concentrations despite eculizumab treatment had improved hematologic outcomes and reduced fatigue after i... Trial registration numbers: PADDOCK (NCT02588833), PRINCE (NCT04085601; EudraCT, 2018-004220-11), PEGASUS (NCT03500549)....